Recent Healthcare Financings
| Company Name | Amount Raised | Type of Fundraise | Country | Date |
| Private Company Financings | ||||
| Syneron Bio | $150 million | Series B | US | 3 April |
| Stipple Bio | $100 million | Series A | US | 6 April |
| Sidewinder Therapeutics | $137 million | Series B | US | 8 April |
| Life Biosciences | $80 million | Series B | US | 8 April |
| Oricell Therapeutics | $110 million | “Pre-IPO round” | China | 10 April |
| Vivatides Therapeutics | $54 million | Series A | US | 10 April |
| Neomorph | $100 million | Series B | US | 13 April |
| Beeline Medicines | $300 million | Series A | US | 15 April |
| Terremoto Biosciences | $108 million | Series C | US | 15 April |
| Storm Therapeutics | $56 million | Series C | UK | 16 April |
| Kelonia Therapeutics | $7 billion | Acquisition | US | 20 April |
| Ray Therapeutics | $125 million | Series B | US | 21 April |
| Tortugas Neuroscience | $106 million | Seed/Series A | US | 21 April |
| Fathom Therapeutics | $47 million | Series A | US | 27 April |
| Coultreon Biopharma | $125 million | Series A | US | 28 April |
| EnteroBiotix | $25 million | Undisclosed | UK | 29 April |
| Vivacta Biotechnology | $50 million | Series A & A+ | China | 29 April |
| Public Company Financings | ||||
| Trevi Therapeutics | $173 million | Public offering | US | 15 April |
| Adlai Nortye | $150 million | Private placement | China | 16 April |
| Prelude Therapeutics | $90 million | Public offering | US | 20 April |
| Kailera Therapeutics | $718.8 million | Public offering | US | 20 April |
| Nektar Therapeutics | $325 million | Public offering | US | 21 April |
| Altimmune | $225 million | Public offering | US | 22 April |